SLU-PP-332 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Published murine studies used intraperitoneal administration twice daily (25 to 50 mg/kg). Daily mcg values above are expressed for a 25 g mouse. No reputable sources support once-daily subcutaneous use for this compound.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 1.67 mg/mL, 1 unit = 0.01 mL » 16.7 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; avoid freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation.
• Protect from light during storage and handling.

Supplies Needed

Based on an 8 to 16 week murine-equivalent protocol with twice-daily administration.

Peptide Vials (SLU-PP-332, 5 mg each):

• 8 weeks: ~25 vials. 12 weeks: ~39 vials. 16 weeks: ~53 vials.

Insulin Syringes (U-100):

• Per week: 14 syringes (2/day).
• 8 weeks: 112. 12 weeks: 168. 16 weeks: 224.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (25 vials): 8 bottles. 12 weeks (39 vials): 12 bottles. 16 weeks (53 vials): 16 bottles.

Alcohol Swabs:

• 8 weeks: 224 (3 x 100-count). 16 weeks: 448 (5 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• No human data: SLU-PP-332 has not been tested in human subjects; all evidence is from murine

models.

• Use new sterile syringes for each administration; dispose in a sharps container.
• Rotate injection sites to reduce local irritation.
• Document administration times, doses, and any observations.
• This compound is for research purposes only and is not for human consumption.

How This Works

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRa, ERRb, and ERRg), with strongest activity at ERRa. In murine studies, acute administration activated an aerobic-exercise transcriptional program, increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle, and improved endurance capacity and cardiometabolic phenotypes. The compound acts as an exercise mimetic by engaging metabolic pathways typically activated during physical training, without requiring the mechanical stress of actual exercise. All evidence to date is preclinical.

Benefits & Side Effects

Findings from murine studies only.

• Metabolic effects: Enhanced mitochondrial function, increased fatty-acid oxidation, improved glucose

tolerance in diet-induced obese mice.

• Cardiac benefits: Ameliorated heart failure through enhanced cardiac fatty-acid metabolism and

mitochondrial function in preclinical models.

• Endurance enhancement: Increased treadmill running capacity and muscle oxidative capacity in mice.
• Renal effects: Reversed mitochondrial dysfunction and inflammation in aging kidney models.
• Human safety unknown: No data on human tolerability, pharmacokinetics, or adverse effects exist.

Lifestyle Factors

Complementary strategies for best outcomes.

• Diet composition (standard vs. high-fat) influenced metabolic outcomes in published studies.
• SLU-PP-332 was studied alongside exercise training in some murine models, suggesting potential

synergistic effects.

• Environmental controls (temperature, housing) should be standardized in research protocols.
• Compound stability and handling procedures are critical for reproducible results.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry completely.
2. For subcutaneous administration: pinch a skinfold; insert needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Note: Published murine studies used intraperitoneal administration; subcutaneous route is not validated for this compound.

References

Source citations for further reading.

1. Synthetic ERRa/b/g Agonist Induces ERRa-Dependent Acute Aerobic Exercise Response (ACS Chemical Biology, 2023).
2. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhanced Cardiac Fatty Acid Metabolism (Circulation, 2024).